These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 224827)

  • 1. [The leukocyte migration inhibition test (LMIT) in recurrent herpes simplex labialis. Comparison of the results of treatment with BCG and Levamisole (author's transl)].
    Jarisch R; Sandor I; Cerni C
    Arch Dermatol Res; 1979 May; 265(1):15-22. PubMed ID: 224827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of recurrent herpes simplex and its surveillance by MIF determination: with levamisole, BCG, urushiol and herpes antigen vaccine (author's transl)].
    Jarisch R; Sandor I
    Arch Dermatol Res (1975); 1977 Apr; 258(2):151-9. PubMed ID: 141241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to herpes simplex virus in patients with recurrent herpes labialis: I. Development of cell-mediated cytotoxic responses.
    Tsutsumi H; Bernstein JM; Riepenhoff-Talty M; Cohen E; Orsini F; Ogra PL
    Clin Exp Immunol; 1986 Dec; 66(3):507-15. PubMed ID: 2436840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocyte migration inhibitory factor in HSV infections.
    Centifanto YM; Zam ZS; McNeill JI; Kaufman HE
    Invest Ophthalmol Vis Sci; 1978 Sep; 17(9):863-8. PubMed ID: 212384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human T cell response to Herpes simplex virus antigen in vitro.
    Berle EJ; Thorsby E
    Acta Pathol Microbiol Scand C; 1980 Feb; 88(1):31-7. PubMed ID: 6246714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to herpes simplex virus in patients with recurrent herpes labialis. II. Relationship between interferon production and cytotoxic responses.
    Tsutsumi H; Bernstein JM; Riepenhoff-Talty M; Ogra PL
    Pediatr Res; 1986 Sep; 20(9):905-8. PubMed ID: 3018660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of recurrent herpes simplex labialis with levamisole.
    Spruance SL; Krueger GG; MacCalman J; Overall JC; Klauber MR
    Antimicrob Agents Chemother; 1979 May; 15(5):662-5. PubMed ID: 525982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell mediated immunity to herpes simplex in man. IV. A correlation of lymphocyte stimulation and inhibition of leukocyte migration.
    Russell AS; Kaiser J; Lao VS
    J Immunol Methods; 1976; 9(3-4):273-9. PubMed ID: 175120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on human epidermal Langerhans' cells: II. Activation of human T lymphocytes to herpes simplex virus.
    Braathen LR; Berle E; Mobech-Hanssen U; Thorsby E
    Acta Derm Venereol; 1980; 60(5):381-7. PubMed ID: 6162307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Specific and unspecific immune stimulation in recurrent herpes simplex].
    Raab W
    Z Hautkr; 1977 May; 52(10):565-72. PubMed ID: 195407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Herpes simplex virus (hsv-1 and hsv-2) infection: its clinical and oncogenic properties (author's transl)].
    Dostal V; Fanta D; Reiss-Gutfreund RJ
    Wien Klin Wochenschr; 1977 Nov; 89(22):741-8. PubMed ID: 201107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination].
    Hippmann G; Wekkeli M; Rosenkranz AR; Jarisch R; Götz M
    Wien Klin Wochenschr; 1992; 104(7):200-4. PubMed ID: 1523844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immune responses to Herpes simplex virus type 1 in recurrent herpes labialis: in vitro blastogenesis and cytotoxicity to infected cell line.
    Steele RW; Vincent MM; Hensen SA; Fuccillo DA; Chapa IA; Canales L
    J Infect Dis; 1975 May; 131(5):528-34. PubMed ID: 165245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential changes in cell-mediated immune responses to herpes simplex virus after recurrent herpetic infection in humans.
    Shillitoe EJ; Wilton JM; Lehner T
    Infect Immun; 1977 Oct; 18(1):130-7. PubMed ID: 198372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-mediated immunity to herpes simplex virus types 1 and 2 antigens in leukoplakia and carcinoma in man.
    Shillitoe EJ; Tarro G; Lehner T
    Oncology; 1976; 33(4):192-5. PubMed ID: 65753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Levamisole in the therapy of recurrent herpes simplex labialis].
    de Campos Machado JA
    Cent Estud Recur Odontol Nino; 1980 Apr; 5(1):39-42. PubMed ID: 6933025
    [No Abstract]   [Full Text] [Related]  

  • 17. Preliminary evaluation of immunotherapy in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Karpowicz M; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Małkowska-Zwierz W; Pawelski S
    Arch Immunol Ther Exp (Warsz); 1981; 29(6):739-55. PubMed ID: 7349093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of recurrent herpetic disease with specific inactive antigen].
    Zábrodský S; Benda R
    Cesk Stomatol; 1980 Jul; 80(4):267-72. PubMed ID: 6250729
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular immunity and circulating antibody to herpes simplex virus in subjects with recurrent herpex simplex lesions and controls as measured by the mixed leukocyte migration inhibition test and complement fixation.
    Gange RW; de Bats A; Park JR; Bradstreet CM; Rhodes EL
    Br J Dermatol; 1975 Nov; 93(5):539-44. PubMed ID: 173386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological responses of patients with recurrent herpes genitalis.
    Sirianni MC; Bonomo R; Scarpati B; Soddu S; Panà A; Turbessi G; Cherchi M; Aiuti F
    Diagn Immunol; 1986; 4(6):294-8. PubMed ID: 3493109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.